Valuation: OLIPASS Corporation

Market Cap 26.53B 18.73M 16.22M 15.2M 13.86M 26.07M 1.79B 26.47M 179M 69.88M 894M 70.31M 68.78M 2.98B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.35M 12.44M 11.65M 10.63M 19.98M 1.37B 20.29M 137M 53.57M 685M 53.89M 52.72M 2.29B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 2025-05-21
Corporate Officer/Principal 34 2024-11-27
Comptroller/Controller/Auditor 67 2025-03-30
Director TitleAgeSince
Director/Board Member 54 2024-11-27
Director/Board Member 34 2024-11-27
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-92.37% 9.53M
-0.73%+12.52%+74.33%+102.34% 70.51B
+1.60%+1.66%+37.76%+66.48% 54.05B
+0.09%+33.91%+8.69%+494.62% 28.95B
-0.61%+12.95%+53.77%+5.42% 24.05B
+0.69%+1.18%-15.97%-13.19% 23.31B
-1.37%+18.52%+255.24%+464.53% 18.67B
+2.21%+7.66%+47.18%-19.64% 18.37B
0.00%+9.69%+31.01%+584.59% 16.1B
-1.51%-10.95%+33.04%+134.73% 12.72B
Average -1.38%+3.70%+52.51%+172.75% 26.67B
Weighted average by Cap. +0.11%+10.12%+56.25%+166.41%

Financials

2021 2022
Net sales 852M 601K 521K 488K 445K 837K 57.34M 850K 5.74M 2.24M 28.71M 2.26M 2.21M 95.74M 2.3B 1.62M 1.4M 1.32M 1.2M 2.26M 155M 2.29M 15.47M 6.05M 77.39M 6.08M 5.95M 258M
Net income -25.13B -17.74M -15.37M -14.4M -13.13M -24.69M -1.69B -25.07M -169M -66.21M -847M -66.61M -65.16M -2.83B -24.17B -17.06M -14.78M -13.85M -12.63M -23.74M -1.63B -24.11M -163M -63.66M -815M -64.04M -62.65M -2.72B
Net Debt -18.29B -12.91M -11.18M -10.48M -9.56M -17.97M -1.23B -18.25M -123M -48.18M -617M -48.47M -47.42M -2.06B -6.2B -4.37M -3.79M -3.55M -3.24M -6.09M -417M -6.18M -41.75M -16.32M -209M -16.42M -16.06M -696M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock